Revolution Medicines CFO Disposes Shares to Satisfy Tax Withholding Under 10b5-1 Plan

Executive Summary

On September 18, 2026, Revolution Medicines, Inc. ($RVMD) filed a Form 4 disclosing open-market dispositions of common stock by Chief Financial Officer Jack Anders on September 16, 2026. The insider disposed of an aggregate of 4,053 shares across two transaction blocks totaling approximately $807,513.37.

Transaction Details

• Date: September 16, 2026
• Tranche 1: 61 shares sold at $195.00 per share.
• Tranche 2: 3,992 shares sold at a weighted average price of $199.3032 per share.
• Total Disposed: 4,053 shares
• Gross Proceeds: $807,513.37
• Ownership Post-Transaction: 119,216 shares directly held (including 43,650 restricted stock units).

Context & Trading Significance

The transaction is categorized as Low trading significance due to the following factors:

1. Mandated/Routine Nature: As noted in the footnotes, the transactions were conducted pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, specifically to satisfy tax withholding obligations triggered by the vesting of restricted stock units (RSUs).
2. Holding Retention: Following the transaction, the insider continues to hold 119,216 shares, retaining the substantial majority of his equity stake.
3. Absence of Discretionary Selling: Pre-scheduled sell-to-cover transactions typically do not reflect executive sentiment regarding the company's operating performance or forward outlook.